https://pioneerinstitute.org/wp-content/uploads/Patents-arent-evil.png 512 1024 William Smith https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png William Smith2023-05-15 13:12:342023-05-31 11:45:08Opinion: Drug patents aren’t a ‘necessary evil.’ They save lives.
Drug patents are one of the most important public policy innovations in all of human history, and a boon to patients awaiting cures. Inventions only come when inventors are rewarded, not punished. Patents are not a “necessary evil.”
https://pioneerinstitute.org/wp-content/uploads/Copy-of-work-force.png 512 1024 Editorial Staff https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Editorial Staff2023-05-15 09:00:202023-05-15 15:38:49Study: High List Prices and Deep Discounts for Prescription Drugs Hurt Poor and Sick Patients
A new Pioneer Institute study illustrates how the current system of drug pricing and discounts leads to patients with challenging diseases being charged huge out-of-pocket sums to keep other premiums low, effectively imposing financial penalties on the sick to protect the healthy and wealthy.
https://pioneerinstitute.org/wp-content/uploads/Pioneer-Institute-Statement-on-Question-1-1.png 512 1000 Editorial Staff https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Editorial Staff2023-01-11 07:43:522023-01-11 07:44:28First-of-Its-Kind Interactive Mapping Tool Reveals Extent of For-Profit Entities Benefitting from the 340B Drug Pricing Program
Today, Pioneer Institute released a first-of-its-kind, 50-state mapping tool and database highlighting the troubling way in which hospitals and covered entities leverage unlimited pharmacy contracts under the 340B Drug Pricing Program.
https://pioneerinstitute.org/wp-content/uploads/340-web-post.png 900 1600 Editorial Staff https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Editorial Staff2022-03-22 05:41:312022-03-25 14:38:00Massachusetts Hospitals Pull Back on Charity Care as Revenue from Federal 340B Drug Discount Program Explodes
Over the past decade, the revenue for hospitals generated by the federal 340B drug discount program, initially intended to serve low-income, uninsured populations, has exploded even while a number of important Massachusetts hospitals have reduced the level of charity care they provide, according to a new study published by Pioneer Institute. The Pioneer Institute study, “340B Drug Discounts: An Increasingly Dysfunctional Program,” notes that nationwide, 340B drug sales rose from $9 billion in 2014 to $38 billion in 2020.
https://pioneerinstitute.org/wp-content/uploads/Untitled-design-2021-12-06T120924.383.png 512 1024 Editorial Staff https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Editorial Staff2021-12-06 11:44:202021-12-06 12:10:01The Promise and Challenges of Rare Cancer Treatments
Dr. William Smith, Pioneer Institute's Visiting Fellow in Life Sciences, spoke about the challenges and opportunities for rare cancer treatments, in a video interview produced by Rare Cancers, a patient group based in Australia, for the November 26th CAN Forum.
https://pioneerinstitute.org/wp-content/uploads/NEW-REPORT.png 512 1024 Editorial Staff https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Editorial Staff2021-11-09 05:39:002021-11-09 05:41:06Study: Decline in Cardiovascular Health Screenings During COVID-19 Pandemic Poses New Public Health Threat
Pioneer Institute today released a new analysis focused on cardiovascular disease, An “Impending Tsunami” in Mortality from Traditional Diseases?, that examines how the COVID-19 pandemic has created another unrelated public health crisis. The Pioneer analysis examines how a single-minded public health focus on COVID-19, social distancing, and lockdowns drove reductions in screenings, diagnoses, and early treatment for complex conditions such as heart disease.
https://pioneerinstitute.org/wp-content/uploads/The-QALY-and-Cancer-Treatments_-An-Ill-Advised-Match.png 512 1024 Editorial Staff https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Editorial Staff2021-04-06 04:45:242021-07-19 10:41:05New Analysis: ICER Framework Ignores Patient Preferences, Innovation & Societal Benefits in Evaluating Cost-Effectiveness of New Cancer Treatments
Pioneer Institute today released a new analysis, The QALY and Cancer Treatments: An Ill-Advised Match, that examines the alarming methodological and contextual shortcomings of the Quality Adjusted Life Years (QALY)-based methodology in evaluating new cancer therapies. The Pioneer Institute analysis reveals five specific problems with ICER’s evaluation of cancer treatments and demonstrates the urgent need to prohibit the use of the QALY amid trends in rapid cancer innovations and personalized medicine.
https://pioneerinstitute.org/wp-content/uploads/Five-Reasons-Why-Drug-Rebates-Are-Harmful-to-Patients-and-to-the-Healthcare-System-4.png 512 1024 Editorial Staff https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Editorial Staff2020-10-20 11:20:432020-12-10 16:24:25Study: Growth of Antibiotic-Resistant Infections Could Have Massive Human, Financial Costs
The world was blindsided by COVID-19, but a new Pioneer Institute study finds that even as we continue to wrestle with the pandemic, another threat looms that scientists have long known about but the nation has thus far failed to address: the growth of antibiotic-resistant infections. “Market dysfunction and perverse Medicare reimbursement rates have led to a growth in infections that resist antibiotics,” said Gunnar Esiason, author of “Antimicrobial Resistance: Learning from the current global health crisis to prevent another one.” If we don’t solve this problem, the human and economic costs are likely to be astronomical.”
https://pioneerinstitute.org/wp-content/uploads/Five-Reasons-Why-Drug-Rebates-Are-Harmful-to-Patients-and-to-the-Healthcare-System.png 512 1024 Editorial Staff https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Editorial Staff2020-09-01 06:40:182020-12-11 12:09:06Study: Growing Drug Rebates Hurt Both Consumers and Healthcare System
Ever-larger rebates are distorting the market for branded drugs and producing outcomes that often benefit neither consumers nor the healthcare system, according to a new study published by Pioneer Institute.
https://pioneerinstitute.org/wp-content/uploads/Fresh-Aqua-Summit-1.png 512 1024 Editorial Staff https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Editorial Staff2020-05-21 05:48:362021-11-23 10:32:03Study Finds Pandemic Likely to Negatively Impact Biopharmaceutical Sector
Contrary to conventional wisdom that says the coronavirus pandemic will generally benefit biopharmaceutical companies, a new Pioneer Institute study finds many companies will emerge from the pandemic commercially weaker, dealing with delays in new product launches and with fewer resources to invest in research and development.
https://pioneerinstitute.org/wp-content/uploads/Green-Grunge-Basketball-Quote-UAAP_NCAA-Twitter-Post-1.png 512 1024 Editorial Staff https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Editorial Staff2020-04-02 06:00:242020-12-11 13:28:28New Report: Quality Adjusted Life Years (QALY) Methodology Discriminates Against Older Americans, Threatens to Deny Seniors Access to Life-Saving Care
New report asserts that with older americans more vulnerable during the COVID-19 pandemic, all health plans should avoid using the QALY methodology when assessing the value of care for older patients
https://pioneerinstitute.org/wp-content/uploads/1140-man-wheelchair-disability-aarp.imgcache.rev5804edef486e77e680d3985a3ddb67dd.jpg 655 1140 Editorial Staff https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Editorial Staff2020-02-10 07:00:262021-01-28 15:07:32New Report & Legal Analysis Suggests ICER’s Quality Adjusted Life Years Methodology Violates the Americans with Disabilities Act
A new report, "The Legality of QALY under the ADA," outlines several potential legal violations and negative implications for disabled individuals related to the adoption of the QALY approach to drug value assessment, used most prominently by ICER.
https://pioneerinstitute.org/wp-content/uploads/questionmark-of-pills.jpg 599 900 Editorial Staff https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Editorial Staff2019-06-24 00:01:552019-07-31 15:57:22New Report Addresses Distinct Challenges in Utilizing ICER to Assess Value of Rare Disease Treatments
Pioneer Institute Discourages Policymakers & Payers from…
https://pioneerinstitute.org/wp-content/uploads/GavelSteth.jpg 468 800 Editorial Staff https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Editorial Staff2019-01-24 06:00:002021-01-28 15:11:06Study Urges Caution Before Adopting ICER Reviews to Determine Cost Effectiveness of Treatments
Review methodology could negatively impact elderly, the disabled,…